Treatments for Thrombotic Thrombocytopenic Purpura: Plasma, Vincristine, Hemodialysis and Exchange Transfusions

R. L. Hanzlick, N. T. Shah, D. A. Senhauser, John J. Byrnes, Mohan Khurana, Neil Abramson, Ennio C. Rossi, Francesco Del Greco

Research output: Contribution to journalLetterpeer-review

30 Scopus citations

Abstract

To the Editor: Byrnes and Khurana1 conclude that, in a case of thrombotic thrombocytopenic purpura, remission was achieved by replacement of a deficient, “plasma factor” by transfusion of exogenous plasma. However, they do not convincingly exclude the possibility that the deficient factor was associated with platelets rather than plasma. The data presented on their patient indicate that the first seven successful exchange transfusions were done with fresh whole blood, which include normal fresh platelets. The patient improved, and despite receiving platelets, thrombotic tendencies were not aggravated. Furthermore, the interval between successive relapses varied from five to 11 days, a period.

Original languageEnglish (US)
Pages (from-to)971-972
Number of pages2
JournalNew England Journal of Medicine
Volume298
Issue number17
DOIs
StatePublished - Apr 27 1978

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatments for Thrombotic Thrombocytopenic Purpura: Plasma, Vincristine, Hemodialysis and Exchange Transfusions'. Together they form a unique fingerprint.

Cite this